Welcome to our dedicated page for Chiasma news (Ticker: CHMA), a resource for investors and traders seeking the latest updates and insights on Chiasma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chiasma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chiasma's position in the market.
Chiasma, a biopharmaceutical company, reported its Q1 2020 financial results, revealing a net loss of $15.4 million. The FDA has not announced delays for the MYCAPSSA approval, with a target action date set for June 26, 2020. Chiasma plans to launch MYCAPSSA, the first oral somatostatin analog for acromegaly, in Q4 2020, contingent on FDA approval. General and administrative expenses surged to $7.6 million due to pre-commercial activities, while R&D expenses rose to $8.1 million. Cash reserves decreased from $92.4 million to $79.3 million, with additional financing expected from HCR.
Summary not available.